c-Abl (ABL1) phosphorylates α-synuclein at Y39, promoting aggregation and neuronal toxicity. Nilotinib (FDA-approved for CML) inhibits c-Abl and promotes α-syn clearance via autophagy, representing a rapid translational candidate. However, the hypothesis faces significant challenges: (1) Y39 phosphorylation is less abundant than S129 in human synucleinopathies and its aggregation role is contested; (2) Nilotinib failed its primary endpoint in PD clinical trials (Ko et al. 2020) with no UPDRS improvement; (3) BBB penetration claims are disputed; (4) Nilotinib has multiple off-target effects (DDR1, DDR2) that may explain any apparent neuroprotection independent of c-Abl. The Mechanism Attribution Problem is severe—any observed benefit cannot be confidently assigned to c-Abl inhibition.
Curated pathway from expert analysis
flowchart TD
A["ABL1/c-Abl<br/>Tyrosine Kinase Activation"]
B["Mitochondrial<br/>Dysfunction"]
C["Oxidative<br/>Stress"]
D["p53 Activation<br/>Pro-apoptotic Signaling"]
E["Synaptic<br/>Dysfunction"]
F["Neuronal<br/>Death"]
G["Dasatinib / Nilotinib<br/>Kinase Inhibition"]
A --> B
B --> C
C --> D
D --> F
A --> E
E --> F
G --> A
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for ABL1 yet. Search RCSB →
Median TPM across 13 brain regions for ABL1 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ABL1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF patients with idiopathic PD receive 6 months of nilotinib (300mg daily, the dose used in the Ko et al. 2020 trial) plus standard dopaminergic therapy versus placebo plus standard therapy, THEN stri | No significant difference in F-DOPA Ki values between nilotinib and placebo groups after 6 months; projected effect size <0.15 standardized units. | — no observation — | pending | 0.35 |
| IF ABL1 knockout or ABL1 Y245F kinase-dead knock-in neurons are challenged with preformed α-synuclein fibrils, THEN Y39-phosphorylated α-synuclein will be reduced by >70% and aggregate burden will dec | Y39-pS129 double-positive inclusions will be reduced by >70% in ABL1-deficient neurons; autophagy flux markers (LC3-II/LC3-I ratio) will not differ from baselin | — no observation — | pending | 0.55 |